TABLE 2.
Protection among vaccinated mice against an i.p. or mucosal SEB challenge
| Vaccination dose (route) | No. survived/no. challengeda (% survival)
|
|
|---|---|---|
| i.p. challenge | Mucosal challenge | |
| 20 μg of SEBv + alum (i.p.) | 10/10 (100)b | 8/8 (100)b |
| 10 μg of SEBv + alum (i.p.) | ND | 5/8 (63)b |
| 5 μg of SEBv + alum (i.p.) | 10/10 (100)b | ND |
| Alum only (i.p.) | 0/10 (0) | 0/12 (0) |
| 20 μg of SEBv + 10 μg of CT (oral) | 3/8 (38)c | 6/8 (75)d |
| 10 μg of SEBv + 10 μg of CT (oral) | ND | 5/6 (83)d |
| 2.5 μg of SEBv + 10 μg of CT (oral) | 1/8 (13)c | ND |
| 10 μg of CT (oral) | 0/7 (0) | 0/12 (0) |
| 20 μg of SEBv + 5 μg of CT (nasal) | 8/8 (100)e | 8/8 (100)e |
| 10 μg of SEBv + 5 μg of CT (nasal) | ND | 7/7 (100)e |
| 2.5 μg of SEBv + 5 μg of CT (nasal) | 6/7 (86)e | ND |
| 5 μg of CT (nasal) | 0/6 (0) | 1/10 (10) |
| None | ND | 0/11 (0) |
a
The i.p. challenge consisted of 25 to 30 LD50 of SEB; the mucosal challenge consisted of 7 to 8 LD50 of aerosolized SEB. ND, not determined.
b
Significantly different (P < 0.05) from alum-only control.
c
Not significantly different (P > 0.05) from 10 μg of CT (oral) control.
d
Significantly different (P < 0.05) from 10 μg of CT (oral) control.
e
Significantly different (P < 0.05) from 5 μg of CT (nasal) control.